by Mark Chiang

马克·蒋

Share To

分享到

SHENZHEN, China — MGI Tech Co., Ltd. has unveiled its latest high-throughput sequencer, the DNBSEQ-T7+, which the company describes as a “data mining machine” for genomics research. The announcement was made on September 14, 2025, and highlights the device’s capabilities in addressing growing demands for advanced sequencing technologies in life sciences..

中国深圳——华大智造科技股份有限公司发布了其最新的高通量测序仪DNBSEQ-T7+，该公司将其描述为基因组学研究的“数据挖掘机”。该消息于2025年9月14日发布，并强调了该设备在满足生命科学领域对先进测序技术日益增长需求方面的能力。

According to MGI, the DNBSEQ-T7+ is designed to deliver enhanced performance for large-scale genomic projects. The new system builds on previous models with improved throughput and efficiency, aiming to support researchers working on complex datasets. While specific technical specifications were not disclosed in the announcement, the company emphasized that this next-generation sequencer is tailored to meet evolving needs in genomics and related fields..

根据MGI介绍，DNBSEQ-T7+ 旨在为大规模基因组项目提供增强的性能。该新系统在以往型号的基础上提升了通量和效率，旨在支持研究人员处理复杂的数据集。尽管具体技术规格尚未在公告中披露，但公司强调，这款下一代测序仪专为满足基因组学及相关领域不断变化的需求而设计。

Newsflash | Powered by GeneOnline AI

新闻快讯 | 由GeneOnline AI提供支持

Source: GO-AI-ne1

来源：GO-AI-ne1

Date: September 15, 2025

日期：2025年9月15日

Related posts:

相关内容：

HHS Cuts Lead to Research Staff Reductions at ASPE and AHRQ

HHS的削减导致ASPE和AHRQ的研究人员减少

Merck KGaA to Acquire SpringWorks Therapeutics After Deliberation

默克公司计划在深思熟虑后收购SpringWorks Therapeutics。

FDA Forum Addresses Regulatory and Manufacturing Challenges in Gene Therapy Development

FDA论坛探讨基因治疗开发中的监管和制造挑战

Study Reveals Link Between Vasomotion Disruptions and Neurological Disorders

研究揭示了血管运动障碍与神经系统疾病之间的联系

©www.geneonline.com All rights reserved. Collaborate with us:

©www.geneonline.com 版权所有。与我们合作：

[email protected]

电子邮件地址

Author

作者

Mark Chiang

马克·蒋

Related Post

相关文章

News Flash

新闻快讯

Kelyniam Global to Present at Life Sciences Virtual Investor Forum on September 18, 2025

凯尔尼全球将于2025年9月18日生命科学虚拟投资者论坛上发表演讲。

2025-09-15

2025年9月15日